Stockreport

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF -- STK-001 is a potential new disease-modifying medicine for the treatment of Dravet syndrome, a severe and progressive form of genetic epilepsy -- BEDFORD, Mass.--(B [Read more]